^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis
Published date:
11/11/2021
Excerpt:
We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment....The BCL2 super-expressors (n = 35) showed significantly worse event-free survival (EFS; HR, 1.903; 95% CI, 1.159-3.126, P = 0.011) and overall survival (OS; HR, 2.467; 95% CI, 1.474-4.127, P = 0.001)...
DOI:
10.1038/s41379-021-00962-z
